Clinical Trials in Iceland

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12430 total CTIS records — a stated recency window, not the full historical archive. Synced 17 Sep 2026, 08:35 UTC

2500

Shown in this register

most recently authorised

12,430

Total on CTIS

full historical archive

747

Phase III

within the shown window

Top member states

Spain 1023 France 891 Germany 862 Italy 741 Poland 589 Netherlands 528

Narrow the registerReset

Search within results

Phase

Lead sponsor

Member state

All 28 states

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase II

Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)

2025-523725-17-00HIV-1 disease

Region Midtjylland

Immune System Diseases

Sweden, Norway, Denmark, Iceland

13/07/2026

Phase IV

A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia

2025-524044-35-00Dyspepsia

Landspitali

Digestive System Diseases

Iceland

06/02/2026

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-europe/country/iceland

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.